Regulatory document
European Medicines Agency public statement on valdecoxib and parecoxib sodium…
EMA · Information · EU · Dec 15, 2004
Key facts
| Title | European Medicines Agency public statement on valdecoxib and parecoxib sodium. Cardiovascular risks in coronary artery bypass graft surgery and serious adverse skin reactions |
|---|---|
| Issuer | European Medicines Agency |
| Source | EMA |
| Document type | Information |
| Country or region | EU |
| Date | Dec 15, 2004 |
| Document | ema.europa.eu |
| Issuer website | ema.europa.eu |
At a glance
- Yes Full text searchable in Orca1
- 1,000+ Documents from this issuer in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Global regulations and guidance
Regulations, guidance and official notices from medical device and medicines regulators worldwide, collected by Orca1 from each issuer's website. Only the title, issuer, date and link are shown here; the full text is searchable in Orca1.
Source: Medical device and medicines regulators and agencies as named on each record (EMA, MHRA, TGA, CDSCO, PMDA, NMPA, Health Canada, HSA, the FDA and others), collected by Orca1 from each issuer's website · Source date: